In July 2021, Nebion AG, the company developing GENEVESTIGATOR^® and Genevisible, was acquired by Immunai Inc., a biotech company focusing on developing immunomodulatory drugs using a combination of single-cell multiomics technologies with machine learning. As part of the integration of our technologies, the decision was taken to phase out Genevisible. Instead, we recommend you to use the GENEVESTIGATOR^® platform, which is freely available for academic users.